Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
ACRV Stock Chart & Stats
$1.39
-$0.20(-3.17%)
At close: 4:00 PM EST
$1.39
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.05 - $3.56
Previous CloseN/A
Volume1.72K
Average Volume (3M)996.44K
Market Cap
$56.57M
Enterprise Value$7.28M
Total Cash (Recent Filing)$118.58M
Total Debt (Recent Filing)$2.71M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
May 20, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding38,744,446
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$13.67Price Target Upside883.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Efficacy In Serous SubtypeACR-368 demonstrated notably higher response rates in serous endometrial cancer compared with other subtypes, indicating differentiated activity that may translate into a meaningful clinical opportunity for that patient group.
Regulatory Pathway And Trial ExpansionA registrational trial focused on serous disease has regulatory alignment and is being expanded across the US and Europe, creating a clear pathway toward potential accelerated approval if prospective results confirm current signals.
Safety And Tolerability ProfileClinical safety was characterized mainly by transient blood-related side effects with no major gastrointestinal, lung, or peripheral nerve toxicities reported, supporting a tolerable profile for broader use.
Bears Say
Data Limitations And Need For Prospective ConfirmationEfficacy signals are based on a small, retrospective patient cohort and may not replicate in larger prospective trials, which reduces confidence in the durability of the observed benefit.
Development Strategy And Funding RiskPursuit of multiple development strategies and reliance on a single-arm registrational approach, combined with modest cash resources relative to development spending, creates execution, regulatory, and funding risk for ongoing programs.
Limited Addressable MarketThe serous subtype represents a relatively small portion of endometrial cancer patients, which may limit the overall addressable market despite the high unmet medical need in that subgroup.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.05 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $56.57M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is May 20, 2026 which is in 47 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.483 by -$0.007.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 38,744,446 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.483. Following the earnings report the stock price went up 3.659%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (883.45% Upside)
$13.67 (883.45% Upside)
Insider Transactions
Bought Shares
Worth $114.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
-53.71%
Trailing 12-Months
Asset Growth
-32.32%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$13.67
▲(883.45% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
44.33% Insiders
2.55% Mutual Funds
34.96% Other Institutional Investors
15.77% Public Companies and Individual Investors
Options Prices
Currently, No data available
---